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Abstract
Background: Self-monitoring is increasingly recommended as a method of managing cardiovascular disease.
However, the design, implementation and reproducibility of the self-monitoring interventions appear to vary
considerably. We examined the interventions included in systematic reviews of self-monitoring for four clinical
problems that increase cardiovascular disease risk.
Methods: We searched Medline and Cochrane databases for systematic reviews of self-monitoring for: heart failure,
oral anticoagulation therapy, hypertension and type 2 diabetes. We extracted data using a pre-specified template
for the identifiable components of the interventions for each disease. Data was also extracted on the theoretical
basis of the education provided, the rationale given for the self-monitoring regime adopted and the compliance
with the self-monitoring regime by the patients.
Results: From 52 randomized controlled trials (10,388 patients) we identified four main components in self-
monitoring interventions: education, self-measurement, adjustment/adherence and contact with health
professionals. Considerable variation in these components occurred across trials and conditions, and often
components were poorly described. Few trials gave evidence-based rationales for the components included and
self-measurement regimes adopted.
Conclusions: The components of self-monitoring interventions are not well defined despite current guidelines for
self-monitoring in cardiovascular disease management. Few trials gave evidence-based rationales for the
components included and self-measurement regimes adopted. We propose a checklist of factors to be considered
in the design of self-monitoring interventions which may aid in the provision of an evidence-based rationale for
each component as well as increase the reproducibility of effective interventions for clinicians and researchers.
Background
As cardiovascular disease (CVD) is still the leading
cause of death worldwide, better methods are needed to
m a n a g eC V Dr i s k[ 1 ] .O n ei n c r e a s i n g l yc o m m o n
method is self-monitoring to improve the adjustment
and effectiveness of long-term treatments,[2-5] and
guidelines indicate self-monitoring in several CVD areas.
Heart failure (HF) patients can self-monitor weight and
adjust therapy in response to treatment [6]. Patients
with atrial fibrillation requiring anticoagulation can self-
monitor their INR levels, [7,8] and those with high
blood pressure (BP) can self-monitor at home[9]. How-
ever, not all self-monitoring is effective: self-monitoring
of blood glucose in non insulin treated diabetics is also
recommended[10] but recently randomised trials have
questioned its value[11]. The effectiveness of self-
monitoring reported in different clinical trials varies
substantially. Even a cursory scan of these trials shows
that this variation might be explained at least in part by
the substantial variation in how the self-monitoring was
done in each trial.
Self-monitoring has long been part of behaviour
change in the psychological field where it was used in a
more subjective self-assessment mode [12]. To be effec-
tive in the medical context three minimum criteria are
required: firstly, clinically significant changes in the con-
dition are possible over time; secondly, an objective test
exists that reliably detects these changes; and finally a
cost effective action in response to the test result is pos-
sible[13]. * Correspondence: alison.ward@dphpc.ox.ac.uk
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any medium, provided the original work is properly cited.One of the early examples of self-monitoring was an
asthma programme developed for children [14,15]. This
programme was informed by the early work on self-
efficacy by Bandura [16] and included the patient as an
active participant in the management of their illness.
Self-monitoring is itself a complex intervention made up
of a number of components which can act both inde-
pendently and interdependently[17-19]. The necessity
and relative value of these individual components is
poorly understood, even though understanding how
complex interventions work is important for effective
implementation[20]. Yet in CVD these complex inter-
ventions have been widely adopted with little under-
standing of their active component parts. Therefore to
better understand the components that make up self-
monitoring interventions for CVD from randomised
trials we chose to analyse trials in oral anticoagulation,
hypertension, blood glucose in type 2 diabetes and heart
failure.
Methods
We selected published systematic reviews that evaluated
the effects of self-monitoring of CVD in four specific
areas: 1) oral anticoagulation 2) hypertension, 3) dia-
betes and 4) heart failure. We searched MEDLINE
(1950 to Dec 2008) using a combination of MeSH terms
and free-text keywords, limiting our searches to sys-
tematic reviews using a HIRU hedge for systematic
reviews. The Cochrane Database of Systematic Reviews
(CDSR) and the Database of Abstracts of Reviews of
Effectiveness (DARE) were searched using the same
terms through the Cochrane Library (2008, Issue 4). We
used a cascade approach to locate further reviews by
hand searching retrieved articles and citation searches of
these articles. Inclusion criteria for each disease were:
the most recent systematic review of randomized con-
trolled trials of self-monitoring interventions. We then
retrieved the full text published randomized controlled
trials (RCTs) cited in the systematic reviews.
In a previous study we developed a template to assess
whether a clinician could use the treatment described in
a randomized trial with a patient tomorrow [21]. Based
on this template three of the authors (PG, AW, CH)
designed extraction tables which included all the ele-
ments of self-monitoring interventions which we consid-
ered would be needed to be able to reproduce an
intervention. We divided these into two tables: one for
all the elements related to education and training and
one for all elements of monitoring. We piloted these
extraction tables within the anticoagulation RCTs. We
then added a third table which covered the theoretical
basis of the education provided, the rationale given for
the self-measurement regime adopted and the compli-
ance with the regime by the patients. We then extracted
the components for each disease using the three data
extraction tables. The data extracted for the education
component were: delivery, number, length, mode, con-
tent and assessment of training sessions. The data
extracted for the monitoring component were: interval
between measurements, recording of measurements,
what is adjusted and by whom, adjustment algorithm,
contact with health professionals, when to contact clinic,
quality control of home measurement and transmission
of data to study coordinators. All data extraction was
checked by a second author and any discrepancies
resolved by consensus.
Results
In total we extracted data from 52 RCTs (10,388
patients): 14 HF trials (4,264 patients); 14 OAT trials
(3,049 patients); 18 BP trials (1,714 patients) and 6
SMBG trials (1,361 patients). Remote monitoring in
heart failure (HF) is effective in reducing all cause mor-
tality (Relative Risk = 0.62 (95%CI 0.45 to 0.85) [2]. Self-
monitoring of INR for patients on oral anticoagulation
therapy leads to fewer thromboembolic events (Odds
Ratio = 0.27 (0.12 to 0.59)), and lower mortality (OR =
0.37 (0.16 to 0.85)) [3]. Self-monitoring of blood pres-
sure leads to reductions in systolic BP of 4.2 mmHg
(95% CI, 1.5 to 6.9) as well as diastolic pressure 2.4
mmHg (95% CI, 1.2 to 3.5) [4]. Self-monitoring of blood
glucose (SMBG) which has been found to be effective
for patients with type 1 diabetes and type 2 diabetes if
they are taking insulin appears not be effective in
improving HbA1c in with patients with type 2 diabetes
using oral hypoglycaemic drugs [5].
Components of self-monitoring
We have summarised the data extracted into four main
component areas forming the self-monitoring interven-
tions described in the trials: a) education b) self-
measurement c) adjustment of (or adherence to)
medication and/or behaviour d) contact with health profes-
sionals. Not all components were evident in every trial, and
in some cases the intervention was too poorly described to
be clear whether or not a component was present.
1) Education
The first component in a self-monitoring intervention is
patient (and sometimes health professional) education.
At its most basic, once patients have been identified as
suitable for self-monitoring they need to be taught how
to use the self-monitoring equipment [22]. However, the
education can also be used to provide patients with
information on disease, management and lifestyle [23].
Initial training may be necessary for the health profes-
sionals involved [24] to deliver an effective education
session. A theoretical basis for the type of training pro-
vided has also been suggested [25,26].
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siderably even for the same clinical problem. In all the
heart failure trials, provision of education was part of
the interventions with ongoing phone contact by study
staff for counselling and education in addition to the
monitoring of signs and symptoms. Nonetheless, the
amount of education varied. One study [22] did not
mention education about heart failure or counselling
during monthly phone calls at all and only reported
education on the operation of the telemonitoring equip-
ment. In contrast another trial provided one-to-one or
group counselling covering disease, management, life-
style and monitoring as well as providing extensive edu-
cational materials. The patients were also assessed
before and after each session and were able to contact
medical staff for advice and help [23]. No trials men-
tioned any theoretical basis for their educational
strategies.
In self-monitoring of INR studies, most trials gave two
to three educational sessions, including an assessment of
competency. One trial [27] based their educational com-
ponent on Social Learning theory [16,28] and many
trials referred to each other to determine the education
strategy [29-32].
In BP self-monitoring trials, education varied from
very comprehensive (education provided to both the
patients and health care providers)[24] to patients sim-
ply being instructed in the use of the monitor[25].
Training and education was based on a theoretical
model in only one trial [26]; the model adopted was the
Health Belief Model [33].
For the self-monitoring of blood glucose trials, educa-
tion ranged from ongoing counselling and education
using an algorithm delivered monthly by a trained
nurse[34] to instructions in the use of a monitor and
renewal of dietary recommendations twice [35]. Again
no theoretical basis was given for delivery of the educa-
tion provided, though one study used behavioural rather
than didactic education as a means of increasing com-
pliance [36].
2) Self-measurement
The obvious defining feature of self-monitoring is self-
measurement. Hence a major focus of the initial educa-
tion was on the “how to” and the interpretation of
self-measurements. Self-measuring regimes have to take
into account the accuracy of the monitoring device, the
run in period required to ensure patients are safe and
effective at self-measuring, the quality assurance of the
monitoring device and the frequency with which
patients are required to self-measure.
Ignoring the evidence underpinning self-measurement
regimes led to poor ongoing research. For example, in
an early trial of blood pressure self-monitoring, daily
self-measurement of blood pressure proved too much
for most patients [37] with only 1/5
th of patients allo-
cated to the intervention completing the trial. Yet 11 of
the 18 hypertension trials asked the patients to measure
daily or more frequently without any rationale given for
doing so [4].
Considerable variation occurred in what patients were
asked to monitor and the extent of external monitoring
in the trials. The minimum heart failure patients were
asked to do was measure their weight, record their med-
ications daily and monitoring by a monthly phone call
by a research coordinator [38]. In contrast, other
patients were asked to electronically measure weight,
blood pressure, heart rate and rhythm twice a day and
transmit results immediately to the study centre[22].
I nt h eI N Rt r i a l s ,o n l yo n es t u d ym e n t i o n e dar a t i o -
nale for the frequency of testing. This trial suggested
testing twice a week was optimal to keep patients within
the target therapeutic range based on previous research
[39]. There was considerable variation between what
patients were told to do and what they actually did in
terms of frequency of INR measurements. For example,
in one trial they were instructed to take 11 measures
over the 6 months and whilst the median number of
measures performed was 17, the range was 2 to 39 [27].
Only 6 trials (43%) mentioned external quality control
of the tests [29,30,40-43].
In the BP trials, self-measurement varied considerably
as well as the mode of recording and the responses to
the readings (self-management or other). This ranged
from patients taking electronic BP self-measures three
times in the morning and evening at least three times a
week with the readings being automatically transmitted
to the study centre, providing patients and physicians
with weekly averages, but compliance with this regime
was not reported [44]. In contrast, in another trial
patients were asked to take two consecutive readings
twice a week and mail results to the study centre once a
month but only 50% of patients were compliant[45]. No
trial gave a rationale for the monitoring regime the
patients were asked to perform which ranged between 1
[46] and 21[47] blood pressure readings per week. Over-
all compliance with the measuring strategies ranged
from 15% to above 90%.
The trials of self-monitoring of blood glucose in
patients with type-2 diabetes varied in the number of
tests patients performed and in whether tests were pre
or post-prandial. Whilst some authors specifically
hypothesised that postprandial changes in glucose were
important [34,35,48,49], none gave any rationale for
their decision on how often patients were asked to test
w h i c hr a n g e df r o m2 4[ 5 0 ]t o4 8[ 3 4 , 4 8 ]t i m e sp e r
month. Reported compliance with testing ranged from
45% to above 90%, however, in some cases patients
tested twice as often as requested, 25 times a week
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was mentioned in only two of the six trials [34,50].
Adjustment/Adherence
In self-monitoring some subsequent action needs to
occur to lead to a clinical change: either adjustment of
treatment or better adherence to treatment. If the pur-
pose of the self-monitoring is to increase motivation or
reinforce behaviour then there appears to be no point in
re-testing before the behaviour has had time to produce
a meaningful change in what is being measured.
For example, the lack of effective blood glucose self-
monitoring [5] where the results of behaviour changes
to diet and exercise do not have time to effect what is
being monitored. An example of where this does work
well is self-management of INR where the test results
inform medication dose adjustments, the effects of
which can be seen in the next test result [3]. The rela-
tively small effect size found in the blood pressure trials
may also be due to the fact that the patients do not
make adjustments in response to their test results or
their tests are too frequent for meaningful changes to
have taken place.
The heart failure trials differed in their aims and conse-
quently in what the patients were asked to do. In more
intense interventions the aim was to provide clinicians
with diagnostic information once or twice daily to
improve titration of medications [22]. In direct contrast
other trials were designed to do less self monitoring and
more self-care, while adjustments of therapy were mini-
mal[38]. Patients carried out their own dose adjustments
in two-thirds (64%) of the INR trials but in only one of
the blood pressure trials [51] where adherence to
medication was more often the purpose of the self-
monitoring rather than adjustment of therapy. In the dia-
betes trials the patient self-adjustments were to lifestyle
and nutrition with any medication adjustments being car-
ried out by an external health professional [35,36,48,50].
Health care professionals
It is clear that the purpose of the contact with health
professionals in many of the trials was to increase com-
pliance with medication and measurement and provide
physicians with information for therapy adjustment.
Contact with health professionals was also a way of peri-
odically reinforcing or updating education. However, it
is not clear how much contact is optimal and whether
contact is best by phone, home visit, clinic visit or
computer.
In most of the heart failure trials the purpose of the
contact was mainly for monitoring symptoms, medica-
tion, adherence and education and advice. The health
professionals contacting the patients were mainly
nurses with only two trials using pharmacists [52,53]
and one a research co-ordinator[38]. The mode of con-
tact was phone in all but two trials where videoconfer-
encing was used[54,55]. The amount of contact varied
from three calls by a pharmacist over 6 months [52] to
17 calls from a nurse (median 14 range 11 to 22) over
6 months[56].
In the INR trials the ongoing contact was mainly for
safety. Contact was either with clinicians or nurses and
in one study a pharmacist also contacted patients
monthly [42]. Some patients were able to contact a 24
hour help desk,[29]or a clinician available 24 hours [27]
or during work hours [40] though in most trials patients
were given instructions on when they needed to contact
a health professional.
In the BP trials the purpose of the contact with health
professionals varied from motivation[57] to medication
adjustment during phone calls or clinic visits[44]. Most
of the contacts were with doctors or nurses during clinic
visits but in one case the contact was with a study co-
ordinator who had no health professional training[57],
in another a pharmacist contacted the patients[58] and
in one the contact was with a telephone linked compu-
ter system[46]. The frequency of contact varied from
mean of 1.5 clinic visits (SE 0.1) over 12 months[59] to
weekly phone calls from a nurse for counselling[26].
T h ep u r p o s eo ft h ec o n t a c tw i th health professionals
in the blood glucose trials was both for education and
motivation. Dieticians[35,48,49], doctors and nurses
[34,36,49,50]contacted the patients. The trials were 24
to 28 weeks with five[35] to at least 15[49] contacts
over that period.
Finally, few trials mention a theoretical basis for the
mediating effect of the results of the self-measurement
on the patients’ behaviour. For example, what is the the-
oretical basis for the assumption that the blood pressure
self-monitoring results will increase compliance with
hypertension medication?
Based on the gaps identified we summarised the fac-
tors to be considered at each stage in the design of a
self-monitoring intervention in table 1. These factors
cover aspects related to purpose, people, content and
timing of the four main components of self-monitoring
interventions. Potentially these factors could be used as
a checklist when designing self-monitoring interventions
for CVD disease (table 1). Answering the relevant ques-
tions in the table could not only improve the evidence
base of the interventions but may also make them more
reproducible.
Discussion
Analyses of CVD risk management by self-monitoring
shows considerable variation in the components of the
interventions between trials for the same disease. To
what extent these factors impinge on results is difficult
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outcomes for individual components but also because
the components of an intervention are often poorly
described. In part this will be due to pressures of word
counts in publications of reports [21,60] but it may also
be due to the lack of consideration of the implications
of the decisions made about each component in their
design.
Clinicians use self-monitoring for CVD patients for
different reasons. Blood pressure self-monitoring has
been mainly used to improve adherence to medication
[57] with patients in only one out of 18 trials adjusting
their own therapy[51]. In contrast self-monitoring of
INR in patients on oral anticoagulant therapy is used for
titration of medication either by the patient or the phy-
sician [3]. Self-monitoring in heart failure patients can
be to motivate the patient to improve diet and fluid
intake, adhere to medications and also to provide clini-
cians with information on which to take preventive
action to reduce hospital readmissions [2]. The various
components of the self-monitoring will vary according
to the purpose of the self-monitoring.
Using self-measurement alone to improve adherence
appears to be less successful than when the patient can
make some adjustment in direct response to the test
result. Patients carried out their own dose adjustments
in two-thirds (64%) of the INR trials with a considerable
reduction in mortality OR 0.37 (0.16 to 0.85) [3] but in
only one of the blood pressure trials [51] where the
effect size was much less [4].
The need for evidence-based rationales for the choice
of each component is demonstrated by the poor
Table 1 Self-monitoring components - factors to be considered at each stage in the design of a self-monitoring
intervention
Stage
Factor Education Self-measurement Adjustment/Adherence Health care
professional contact
Purpose What is the purpose?
￿ To increase knowledge
￿ To provide skills
￿ To increase compliance
￿ To increase motivation
What is the purpose?
￿ To provide information
￿ To increase compliance
￿ To increase motivation
What is the purpose?
￿ Titration of medication
￿ Titration of behaviour
￿ Adherence to medication
regime
￿ Adherence to behaviour regime








People Who receives the
education?
￿ Patients
￿ Health care providers
Who is the information for?
￿ Patients
￿ Health care providers
Who adjusts/adheres?
￿ Patients






Content What type of education?
￿ Theoretical basis
￿ Content
￿ Mode of delivery
￿ Support materials
What test is to be used?
￿ Accuracy of the test
￿ Feasibility in this setting
What is adjusted/adhered to?
￿ Medication
￿ Behaviour




Timing What timing is optimal?
￿ Should it be once off
or repeated
￿ How long between
sessions
￿ Is it sustainable
What timing is optimal?
￿ How long should the run in be
What is the frequency of measurements and does
it take account of:
￿ The signal to noise ratio
￿ Fatigue factor and compliance
What is the frequency of
adjustments considering:
￿ The signal to noise ratio
￿ Fatigue factor and
compliance




Other Should the learning be
assessed?
￿ How many assessments




￿ How much re-training
What quality assurance is required?
￿ Internal QA and External QA
￿ How often should QA be conducted?
What is recorded?
￿ How reliable is the recording method
￿ How accurate is the recording method
￿ Is electronic recording available and
feasible
What guidance is provided?
￿ Algorithm
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adopted and lack of efficacy and minimal impact in
some of the trials. Breaking self-monitoring into its
component parts allows analysis and optimisation of
each component. The rationale for each component
needs to be explicit in both the design and reporting of
research interventions and the translation of the inter-
ventions into clinical practice. Table 1 expands each
component by providing a checklist of factors to be con-
sidered. In the long term what is sufficient for each
component needs to be established by the relevant
expert groups for each disease. In the meantime, this
checklist can provide an aid to clinicians and researchers
in the design and reporting of self-monitoring interven-
tions for CVD risk management.
The present overview is limited by only having
access to the published data. This means important
components of the interventions may not have been
reported mainly due to space limitations. In addition,
our components were only based on trials included
within the systematic reviews. Consequently, we may
have missed important trials published subsequently
that may have additional elements which would add to
the components. Methods that improve the descrip-
tions of complex interventions need to be developed.
Previous work has highlighted the importance of better
descriptions complimenting existing systematic review
methodology [21,61].
Conclusions
We propose that self-monitoring for CVD risk manage-
ment can be broken into four major components: edu-
cation, measurement, adjustment/adherence and contact
with health professionals. These components are under-
pinned by a theoretical basis for the mediating effect of
the self-measurement results on behaviour (adjustment
and/or adherence). We have examined the latest sys-
tematic reviews of self-monitoring interventions for
CVD management and found considerable variation in
these components as well as a lack of evidenced-based
rationales for their content. We have proposed a sug-
gested checklist of factors to be considered at each stage
in the design of self-monitoring interventions which
may aid in the provision of an evidence-based rationale
for each component as well as increase the reproducibil-
ity of effective interventions for clinicians and research-
ers. Despite current guidelines for self-monitoring in
CVD management we suggest that for self-monitoring
to be effective in practice all components of self-
monitoring need to be considered.
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